Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Q Biomed Inc (QBIO)

Q Biomed Inc (QBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 26,670
  • Shares Outstanding, K 23,191
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,280 K
  • 60-Month Beta 2.25
  • Price/Sales 1,333.50
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade QBIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.71
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/20/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +587,747.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0900 +2.75%
on 10/19/20
1.3100 -14.50%
on 09/30/20
-0.1400 (-11.11%)
since 09/18/20
3-Month
1.0450 +7.18%
on 09/09/20
1.9500 -42.56%
on 07/30/20
-0.4400 (-28.21%)
since 07/17/20
52-Week
0.3401 +229.31%
on 11/15/19
3.7500 -70.13%
on 02/19/20
+0.6900 (+160.47%)
since 10/18/19

Most Recent Stories

More News
Q BioMed Inc. Discusses Revenue Potential of International Commercialization and Expansion of Strontium89 with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - October 14, 2020) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company,...

QBIO : 1.1200 (-2.61%)
Q BioMed, Inc. CEO Discusses Recently Announced International Market Authorizations and Expansion in to South and Central America and Asia for Q BioMed's Strontium89, its FDA Approved Drug for the Non-Opioid Treatment of Metastatic Cancer in the Bone

SmallCapVoice.com, Inc. ("SCV") today announces the availability of a new interview with Q BioMed Inc. ("the Company") (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses...

QBIO : 1.1200 (-2.61%)
Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe

, /PRNewswire/ -- (OTCQB: QBIO), a commercial stage biotech company, announces initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the...

QBIO : 1.1200 (-2.61%)
Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe

NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announces initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid...

QBIO : 1.1200 (-2.61%)
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program

, /PRNewswire/ -- (OTCQB: QBIO), a commercial stage biotech company, announced today that with its technology partner, Mannin Research, a GMP production contract has been initiated for MAN-19, a clinical...

QBIO : 1.1200 (-2.61%)
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program

NEW YORK , Aug. 26, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that with its technology partner, Mannin Research, a GMP production...

QBIO : 1.1200 (-2.61%)
Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World

NEW YORK , Aug. 11, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today it is launching a Named Patient Program for its...

QBIO : 1.1200 (-2.61%)
QBioMed to Support and Exhibit at Living Beyond Breast Cancer 2020 Virtual Conference on June 13-14, 2020

, /PRNewswire/ -- Q BioMed (OTC: QBIO) is proud to be a Supporter of the Living Beyond Breast Cancer () 2020 Virtual Conference on Metastatic Breast Cancer taking place and 14, 2020. Over 1,100 patients...

QBIO : 1.1200 (-2.61%)
QBioMed to Support and Exhibit at Living Beyond Breast Cancer 2020 Virtual Conference on June 13-14, 2020

NEW YORK , June 12, 2020 /PRNewswire/ -- Q BioMed (OTC: QBIO) is proud to be a Supporter of the Living Beyond Breast Cancer ( LBBC ) 2020 Virtual Conference on Metastatic Breast Cancer...

QBIO : 1.1200 (-2.61%)
Q BioMed Launches New Website Strontium89.com and Digital Marketing Campaign for Strontium89 (Strontium Chloride Sr-89 Injection, USP) Non-opioid Treatment for Metastatic Bone Pain

, /PRNewswire/ --  (OTCQB: QBIO), a commercial stage biotech company, announces the launch of its marketing campaign for its FDA approved non-opioid metastatic bone pain drug Strontium89 (Strontium Chloride...

QBIO : 1.1200 (-2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 1.1800
1st Resistance Point 1.1500
Last Price 1.1200
1st Support Level 1.0900
2nd Support Level 1.0600

See More

52-Week High 3.7500
Fibonacci 61.8% 2.4474
Fibonacci 50% 2.0450
Fibonacci 38.2% 1.6427
Last Price 1.1200
52-Week Low 0.3401

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar